Haleon PLC

Pfizer Inc. has announced the completion of its divestment from Haleon plc, ceasing to be a beneficial owner of the consumer healthcare company's shares following a secondary offering and a share buyback.

Pfizer Inc. has announced the final divestment of its entire 7.3% beneficial ownership in Haleon plc through a secondary block trade offering of 617.55 million shares and a concurrent share buyback by Haleon of 44 million shares, totaling approximately $220 million.

Pfizer Inc. filed an Amendment No. 13 to its Schedule 13D, disclosing its continued beneficial ownership of 7.3% of Haleon plc's Ordinary Shares and the departure of its nominated director, Mr. Supran, following the termination of the Pfizer Relationship Agreement.

Pfizer Inc. has significantly reduced its beneficial ownership in Haleon plc to approximately 7.3% after completing a secondary offering of 700 million Ordinary Shares, generating substantial proceeds.

Pfizer Inc. announced an amendment to its Schedule 13D, detailing a secondary offering of 700 million Haleon plc Ordinary Shares, which will reduce its beneficial ownership to less than 10% and terminate its contractual right to nominate directors to Haleon's Board.

BlackRock, Inc. has filed an amended Schedule 13G, reporting beneficial ownership of 745,718,619 shares of Haleon PLC common stock, representing 8.5% of the class.

Wellington Management Group LLP and its affiliates have reported a 4.97% beneficial ownership stake in Haleon plc common stock as of December 31, 2025.

Wellington Management Group LLP and its affiliates have disclosed a beneficial ownership of 6.85% in Haleon plc's common stock, totaling over 619 million shares, as reported in a recent Schedule 13G filing.

BlackRock, Inc. has filed an amended Schedule 13G, disclosing a 7.3% beneficial ownership stake in consumer health company Haleon PLC as of March 31, 2025.